Therapeutic opportunities involving cellular oncogenes: novel approaches fostered by biotechnology.
Biotechnological processes are having a major impact on many industrial sectors, including the pharmaceutical industry. The contributions of recombinant DNA and hybridoma technologies to modern therapeutics include production of natural and unnatural peptides, subunit vaccines, monoclonal antibodies and nucleic acid hybridization probes for in vitro and in vivo diagnostics and biological imaging, therapeutic monoclonal antibodies as tissue-specific delivery systems or as agents to confer passive immunity, production of therapeutic targets for rational drug design, and the use of cloned enzymes as stereospecific catalysts in large-scale production of small medicinal molecules. Biotechnological advances have led to the identification of a discrete set of genes, oncogenes, which may be essential contributing factors for a great variety and number of human cancers. In addition, biotechnological innovations are fostering the exploitation of oncogenes as novel therapeutic targets for cancer diagnosis, prognosis, and treatment. Because oncogenes are activated in transformation by either qualitative or quantitative mechanisms, however, different biotechnology-based therapeutic approaches are required for each class.
Huber
B E
BE
Wellcome Research Laboratories, Research Triangle Park, North Carolina 27709.
D001709:Biotechnology; D002471:Cell Transformation, Neoplastic; D004345:Drug Industry; D005786:Gene Expression Regulation; D006801:Humans; D009369:Neoplasms / Q000175:diagnosis / Q000503:physiopathology* / Q000628:therapy; D009857:Oncogenes; D011518:Proto-Oncogene Proteins; D011519:Proto-Oncogenes
D011518:Proto-Oncogene Proteins